1,2-Diaminocyclohexane Platinum Derivatives of Potential Clinical Value

  • J. H. Burchenal
  • G. Irani
  • K. Kern
  • L. Lokys
  • J. Turkevich
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 74)

Abstract

Cisdiamminodichloroplatinum (DDP) has assumed an important role in clinical cancer chemotherapy either alone or, more often, in combination with bleomycin, adriamycin, Cytoxan (cyclophosphamide), vindesine, or the arabinosylcytosine (ara-C) derivatives. With these combinations, many investigators have reported on activity in germ cell tumors of the testis, carcinoma of the head and neck, penis, cervix, bladder, lung, esophagus, and ovary [1,7]. It has been used much less in the leukemias and lymphomas. Unfortunately, renal toxicity and severe nausea and vomiting have limited its usefulness, and compounds with less toxicity, greater antitumor effectiveness, and a broader spectrum of activity, including the leukemias and lymphomas, are being sought, particularly those lacking cross-resistance to DDP. As previously reported by various investigators [9, 13], the 1,2-diaminocyclohexane platinum derivatives seem to fit these criteria. In the experimental animal renal toxicity does not appear to be limiting [10], and in mouse leukemia there is no cross-resistance to DDP [2, 3]. The dichloro, malonato, and carboxyphthalato derivatives of 1,2-diaminocyclohexane platinum experimentally have shown a high degree of antitumor effectiveness [9, 13], marked synergism with ara-C derivatives, adriamycin, demethylepipodophyllotoxin ethylidene glucoside (VP-16) [2], and with cyclophosphamide, particularly in combination with various ribonucleotide reductase inhibitors such as hydroxyurea, guanazole, and MAIQ-1 [6]. Clinically, the malonato derivative has been reported by HILL et al. [8] to be clinically active in the acute leukemias, and by RIBAUD et al. [11] to produce remissions in patients whose disease had become clinically resistant to DDP.

Keywords

Lymphoma Platinum Leukemia Oncol Histamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burchenal JH (1978) A clinical overview of dichloro diammino platinum. Biochimie 60:915–923CrossRefGoogle Scholar
  2. 2.
    Burchenal JH, Kalaher K, Dew L, Lokys L, Gale GR (1978) Studies of cross-resistance, synergistic combination and blocking of activity of platinum derivatives. Biochimie 60:961–965CrossRefGoogle Scholar
  3. 3.
    Burchenal JH, Kalaher K, O’Toole T, Chisholm J (1977) Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res 37:3455–3457PubMedGoogle Scholar
  4. 4.
    Burchenal JH, O’Toole T, Kalaher K, Chisholm J (1977) Synergistic effects of the combination of cis-platinum diamminodichloride and 2,2’-anhydro-l-D-arabinofurano- syl-5-fluorocytosine in transplanted mouse leukemias. Cancer Res 37:4098–4100PubMedGoogle Scholar
  5. 5.
    Fischer GA (1958) Studies on the culture of leukemic cells in vitro. Ann NY Acad Sci 76:673–680PubMedCrossRefGoogle Scholar
  6. 6.
    Gale GR, Atkins LM, Meischen SJ, Schwartz P (1978) Schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia. Cancer Treat Rep 63:449–456Google Scholar
  7. 7.
    Gottlieb JA, Drewinko B (1975) Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59:621–628PubMedGoogle Scholar
  8. 8.
    Hill JM, Loeb E, Pardue AS, Khan A, Hill NO, King JJ, Hill RW (1977) Platinum coordination compounds in the treatment of acute leukemia and other malignant diseases with particular reference to malonato 1,2-diaminocyclohexane platinum (II). J Clin Hematol Oncol 7:681–700Google Scholar
  9. 9.
    Meischen SJ, Gale GR, Lake LM, Frangakis CJ, Rosenblum MG, Walker EM, Jr, Atkins LM, Smith AB (1976) Antileukemic properties of organoplatinum complexes. J Nat Cancer Inst 57:841–845PubMedGoogle Scholar
  10. 10.
    Prestayko A, Bradner W, Haftalen J, Rose W, Schurig JE, Cleary MJ, Hydes PC, Crooke ST (1979) Antileukemia (L1210) activity and toxicity of cis-platinum (CDDP II) analogs. Cancer Treat Rep 63:1503–1508PubMedGoogle Scholar
  11. 11.
    Ribaud P, Alcock N, Burchenal JH, Young CW, Muggia F, Mathe G (1979) Preclinical trial in baboon and phase I-II trial and pharmacokinetics in man of malonato platinum (MP). Proc Am Soc Clin Oncol 20:336, abstr #C-186Google Scholar
  12. 12.
    Schindler RS, Day SM, Fischer GA (1958) Culture of neoplastic mast cells and their 5-hydroxytryptamine and histamine content in vitro. Fed Proc 17:1617Google Scholar
  13. 13.
    Schwartz P, Meischen SJ, Gale GR, Atkins LM, Smith AB, Walker EM Jr (1977) Preparation and antitumor evaluation of water-soluble derivatives of dichloro (1,2-di- aminocyclohexane) platinum (II). Cancer Treat Rep 61:1519–1525PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • J. H. Burchenal
  • G. Irani
  • K. Kern
  • L. Lokys
  • J. Turkevich

There are no affiliations available

Personalised recommendations